NCT07226115Recruiting
Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer
Splicing-Based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer (SPLICE)
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Although adjuvant chemotherapy improves survival after curative resection, its efficacy varies widely among patients. The absence of reliable predictive biomarkers often leads to overtreatment or undertreatment. This study aims to develop a machine learning-based predictive model for adjuvant chemotherapy response using tumor-derived alternative splicing signatures. By integrating RNA-seq data, splicing isoform and clinical outcomes, this study seeks to identify molecular predictors of treatment response and recurrence risk after surgery.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 3 Nov 2025
- Start date
- 21 Jun 2024
- Primary completion date
- 18 Jun 2028
- Lead sponsor
- City of Hope Medical Center
- Diseases
- Colorectal cancer
- NCT number
- NCT07226115
What you commit to
- Study type: Observational
- Planned participants: 200
- From 21 Jun 2024 to the primary completion date, 18 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Inflammatory bowel disease
Other
- Inadequate RNA quality or lack of consent
Who the study is looking for
- Histologically confirmed stage II-III colorectal cancer (TNM classification, 8th edition)
- Received standard adjuvant chemotherapy after curative resection
- Availability of tumor tissue (FFPE or frozen) before chemotherapy
- Sufficient clinical data for outcome analysis (recurrence, survival)
- Age 18-80 years Stage
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| City of Hope Medical Center Coordinator of this site? Confirm its status | Duarte | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.